Welcome
The BCLC at the Hospital Clínic of Barcelona is a multidisciplinary team involving all relevant medical specialities devoted to clinical care, research and education in the field of liver cancer. It combines state of the art diagnosis and therapy, with the development of several research projects to evaluate new treatment options. These include laboratory studies in cell cultures or animal models and clinical trials in patients with liver cancer.


Short term fellowships
Recent Publications

JOURNAL ARTICLE
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, 
Bruix J J Hepatology 2018;:10.1016/j.jhep.2018.04.010
Pubmed abstract
JOURNAL ARTICLE
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.

Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, 
Bruix J, Morales A. Oncotarget 2018;24:16701-16717
Pubmed abstract
JOURNAL ARTICLE
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V J Hepatology 2018;:doi: 10.1016/j.jhep.2018.03.019
Pubmed abstract
JOURNAL ARTICLE
Hepatocellular Carcinoma

Alejandro Forner, María Reig, Jordi Bruix

The Lancet 2018;10127:1301-1314
Pubmed abstract
JOURNAL ARTICLE
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, 
Bruix J. Lancet Oncol 2018;5:682-693
Pubmed abstract